Alexander Shabliy accepted a six-month suspension from USADA for testing positive for recombinant erythropoietin, with his ineligibility period starting from March 19, 2025.
Former Bellator lightweight title challenger Alexander Shabliy has taken a six-month suspension from the United States Anti-Doping Agency. This decision follows his positive test for a banned substance during an out-of-competition drug test.
USADA officials broke the news on Wednesday. Shabliy, 32, tested positive for recombinant erythropoietin (rEPO) from a sample collected on March 19, 2025. This substance is prohibited under the PFL Anti-Doping Policy and Prohibited List.
Typically, a violation like this carries a six-month suspension, but it can extend up to a year. However, USADA found Shabliy’s use wasn’t intentional. He also cooperated by providing information about the person who administered the EPO. His suspension started on March 19, 2025.
After serving his time, Shabliy can compete again post-Sept. 19. Recombinant erythropoietin is banned because it boosts red blood cell production, enhancing cardio and conditioning—key for fighters.
Currently, Shabliy fights under the PFL banner. He hasn’t stepped into the ring since losing to lightweight champion Usman Nurmagomedov in September 2024. Now, he’ll be sidelined until at least September 2025.